Skip to main content

Table 3 Multivariate-adjusted mean of fasting glucose, insulin, HOMA-IR, and fructosamine levels according to quartiled Spm + Spd and Spm concentrationsa

From: Association of glycemic profiles with whole blood polyamine among middle-aged Japanese men: colorimetric assay using oat and barley seedling polyamine oxidase

Basic characteristics of study cohort

Quartile of Spd + Spm concentration

P for effectb

P for trendc

Q1 (n = 155)

Q2 (n = 156)

Q3 (n = 156)

Q4 (n = 155)

Fasting plasma glucose (mmol/l)

 Model 1d

5.67

5.56

5.89

5.94

0.019

0.010

 Model 2e

5.96

5.84

6.18

6.25

0.013

0.007

Fasting plasma insulin (μU/ml)

 Model 1

5.60

5.95

5.98

6.21

0.685

0.246

 Model 2

5.88

6.11

6.15

6.40

0.784

0.320

HOMA–IR

 Model 1

1.41

1.47

1.60

1.62

0.282

0.057

 Model 2

1.52

1.55

1.68

1.72

0.329

0.073

Fructosamine (μmol/l)

 Model 1

251

256

256

260

0.213

0.045

 Model 2

261

264

264

268

0.315

0.081

 

Quartile of Spm concentration

P for effectb

P for trendc

Q1 (n = 155)

Q2 (n = 156)

Q3 (n = 156)

Q4 (n = 155)

Fasting plasma glucose (mmol/l)

 Model 1d

5.64

5.76

5.82

5.84

0.493

0.141

 Model 2e

5.92

6.02

6.14

6.12

0.380

0.102

Fasting plasma insulin (μU/ml)

 Model 1

5.79

5.62

6.31

6.07

0.513

0.304

 Model 2

5.95

5.80

6.57

6.24

0.443

0.308

HOMA-IR

 Model 1

1.45

1.46

1.61

1.59

0.453

0.158

 Model 2

1.53

1.54

1.72

1.67

0.338

0.137

Fructosamine (μmol/l)

 Model 1

258

253

257

256

0.647

0.952

 Model 2

267

261

266

264

0.428

0.815

  1. HOMA-IR, Homeostasis model assessment–insulin resistance; Spd, spermidine; Spm, spermine
  2. aQuartiled Spm + Spd and Spm concentrations represented by polyamine-to-hemoglobin ratio
  3. bP value by analysis of covariance
  4. cTest for trend was performed using linear contrast on the assumption of equally-spaced quartiles from low to high
  5. dAdjusted for age and BMI in Model 1
  6. eAdjusted for age, BMI, smoking status, drinking habit, leisure-time physical activity, and present history of chronic disease in Model 2